New Drugs Approved In March


The FDA approved Spravato (esketamine) nasal spray, in combination with an oral antidepressant, for the treatment of adults with treatment-resistant depression, on March 5.

Developed by Janssen Pharmaceuticals, Spravato is said to cost $590 - $885 per treatment session.

Spravato is estimated to achieve sales of $1.3 billion in 2024, according to market research firm EvaluatePharma.

Since the drug has a potential for abuse, Spravato will only be available through a restricted distribution system and it must be administered under the supervision of a certified health care provider.

The drug contains a Boxed Warning of sedation and difficulty with attention, judgment and thinking, abuse and misuse, and suicidal thoughts and behaviors.